Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.69 |
| ▸ | HPGD | P15428 | 7/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 5/20 | 0.64 |
| ▸ | CASP1 | P29466 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | CASP7 | P55210 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283135 | 0.90 | KDM4E (0.84) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL4204293 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL312611 | 0.89 | KDM4E (0.78) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL311959 | 0.88 | HSD17B10 (0.74) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL312553 | 0.87 | KDM4E (0.75) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL14013783 | 0.87 | KDM4E (0.75) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL312555 | 0.86 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL4088135 | 0.86 | HSD17B10 (0.78) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL312295 | 0.86 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL313757 | 0.85 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4708438-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| JP-2008530042-A | — | — | 2008-08-07 | — | — | JP | claimed |
| US-7361659-B2 | Pyrrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | claimed |
| EP-1761541-B1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1851225-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-11-07 | — | — | EP | claimed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | claimed |
| WO-2006084634-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | WO | claimed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | claimed |
| US-8349844-B2 | Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GATTI MCARTHUR SILVIA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-8093263-B2 | Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1851225-B1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-1934214-B1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006084634-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | KDM4E 3638/4885ALDH1A1 1028/4885HSD17B10 4257/4885 |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | KDM4E 1714/4885ALDH1A1 1343/4885HSD17B10 4406/4885 |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | GRM1, GRM2, GRM3 | KDM4E 2684/4885ALDH1A1 617/4885HSD17B10 2867/4885 |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | GRM1, GRM2, GRM3 | KDM4E 1308/4885ALDH1A1 1699/4885HSD17B10 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.